Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8106 | 1218 | 35.1 | 78% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1472 | 7159 | SYSTEMIC LUPUS ERYTHEMATOSUS//LUPUS//LUPUS NEPHRITIS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | LIBMAN SACKS ENDOCARDITIS | Author keyword | 29 | 71% | 2% | 24 |
2 | LUPUS MYOCARDITIS | Author keyword | 4 | 67% | 0% | 4 |
3 | LUPUS CLIN | Address | 3 | 18% | 1% | 16 |
4 | LUPUS ERYTHEMATOSUS SYSTEMIC | Author keyword | 2 | 13% | 1% | 16 |
5 | BLOOMSBURY RHEUMATOL | Address | 2 | 67% | 0% | 2 |
6 | LIBMAN SACKS | Author keyword | 2 | 67% | 0% | 2 |
7 | NON INFECTIOUS ENDOCARDITIS | Author keyword | 2 | 67% | 0% | 2 |
8 | PROGNOSIS STUDIES RHEUMAT DISLUPUS CLIN | Address | 2 | 67% | 0% | 2 |
9 | CARDIAC MANIFESTATIONS | Author keyword | 2 | 30% | 0% | 6 |
10 | LUPUS GRP | Address | 2 | 50% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ACCELERATED ATHEROSCLEROSIS | 55 | 24% | 16% | 200 |
2 | LIBMAN SACKS ENDOCARDITIS | 44 | 63% | 4% | 44 |
3 | CARDIAC ABNORMALITIES | 11 | 21% | 4% | 48 |
4 | CARDIOVASCULAR MANIFESTATIONS | 8 | 20% | 3% | 38 |
5 | ATHEROSCLEROTIC VASCULAR EVENTS | 7 | 67% | 0% | 6 |
6 | DYSLIPOPROTEINEMIA | 6 | 28% | 1% | 18 |
7 | NECROPSY PATIENTS | 6 | 18% | 2% | 28 |
8 | US COHORT LUMINA | 5 | 42% | 1% | 10 |
9 | APOLIPOPROTEIN A1 | 5 | 38% | 1% | 11 |
10 | CONFER INCREASED RISK | 4 | 67% | 0% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review | 2013 | 19 | 37 | 76% |
Accelerated atherosclerosis in patients with SLE-mechanisms and management | 2012 | 39 | 110 | 45% |
'Not only ... but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus | 2005 | 127 | 80 | 59% |
Antiphospholipid syndrome and the heart: A case series and literature review | 2015 | 1 | 91 | 44% |
Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus | 2014 | 5 | 146 | 47% |
Endothelial function and arterial stiffness assessment as early surrogate markers of vascular risk in patients with systemic lupus erythematosus | 2013 | 6 | 55 | 53% |
Cardiovascular disease in lupus: insights and updates | 2013 | 8 | 114 | 43% |
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort | 2000 | 120 | 30 | 47% |
Prediction and management of cardiovascular outcomes in systemic lupus erythematosus | 2015 | 1 | 71 | 28% |
Cardiac pathology of systemic lupus erythematosus | 2009 | 18 | 80 | 68% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LUPUS CLIN | 3 | 18% | 1.3% | 16 |
2 | BLOOMSBURY RHEUMATOL | 2 | 67% | 0.2% | 2 |
3 | PROGNOSIS STUDIES RHEUMAT DISLUPUS CLIN | 2 | 67% | 0.2% | 2 |
4 | LUPUS GRP | 2 | 50% | 0.2% | 3 |
5 | REHAB 32 59 | 2 | 50% | 0.2% | 3 |
6 | LOCOMOTOR SYST | 2 | 33% | 0.3% | 4 |
7 | CENT MANCHESTER MANCHESTER CHILDRENS UNIV HOSP | 1 | 21% | 0.5% | 6 |
8 | CARDIOL RHEUMATOL | 1 | 50% | 0.2% | 2 |
9 | REFERENCE LUPUS SYST | 1 | 100% | 0.2% | 2 |
10 | SERV ENDOCRINOL METAB PREVENT CARDIOVASC | 1 | 50% | 0.2% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000150175 | ANTI TNF ALPHA ANTIBODY INFLIXIMAB//EPIDEMIOL COMPUTAT BIOL//RHEUMATOID CACHEXIA |
2 | 0.0000130959 | LUPUS NEPHRITIS//SYSTEMIC LUPUS ERYTHEMATOSUS//LUPUS |
3 | 0.0000119742 | ANTIPHOSPHOLIPID SYNDROME//ANTIPHOSPHOLIPID ANTIBODIES//LUPUS ANTICOAGULANT |
4 | 0.0000105095 | SCLERODERMA HEART DISEASE//HEART INVOLVEMENT//SMALL CORONARY ARTERY DISEASE |
5 | 0.0000059311 | NONBACTERIAL THROMBOTIC ENDOCARDITIS//MARANTIC ENDOCARDITIS//NON BACTERIAL THROMBOTIC ENDOCARDITIS |
6 | 0.0000055063 | HYDROXYCHLOROQUINE//PLAQUENIL//CHLOROQUINE ADVERSE EFFECTS |
7 | 0.0000051513 | VASCULAR DENDRITIC CELLS//MOL MED CEMM//OPPENHEIMER ATHEROSCLEROSIS |
8 | 0.0000049185 | NEUROPSYCHIATRIC LUPUS//NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS//NEUROPSYCHIATRIC SLE |
9 | 0.0000041210 | ASCENDING AORTIC PSEUDOANEURYSM//AORTIC PSEUDOANEURYSM//AORTIC CANNULATION |
10 | 0.0000039817 | PERICARDIAL MESOTHELIOMA//MALIGNANT PERICARDIAL MESOTHELIOMA//PRIMARY MALIGNANT PERICARDIAL MESOTHELIOMA |